TAKEDA PHARMACEUTICAL CO LTD

# Takeda Pharmaceutical Company Limited

Founded in 1781 and headquartered in Tokyo, Takeda is a multinational pharmaceutical manufacturer focused on specialty and generic drugs. The company engages in the research, development, manufacturing, and marketing of pharmaceutical products across multiple therapeutic areas, including gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. Its marketed brands include Entyvio and Dexilant in gastroenterology, Adcetris and Ninlaro in oncology, Trintellix in neuroscience, and a portfolio of blood disorder treatments such as Advate, Feiba, and Gammagard Liquid.

Takeda maintains an extensive network of in-licensing agreements and collaborative relationships with biopharmaceutical companies including BioMarin, GlaxoSmithKline, Seagen, Neurocrine Biosciences, and others to supplement its internal pipeline. The company operates across major pharmaceutical markets globally, with particular strength in specialty therapeutics and rare disease treatments.

With approximately 47,500 full-time employees, Takeda operates as a large-scale pharmaceutical enterprise with diversified geographic reach across Japan and international markets. The company generates revenue from both branded specialty pharmaceuticals and generic formulations, supported by its substantial research and development infrastructure and manufacturing capabilities.